| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Our patient-centric approach to controlled substance monitoring is backed by more than 150 years of medical knowledge and developed by an award-winning team of pain medicine, primary care, and addiction experts who work collaboratively with the Clinical and Forensic Toxicology Laboratory at Mayo Clinic. Our tests are based on practice guidelines developed by the American Association for Clinical Chemistry Academy and provide clinicians with assistance to ensure patients who receive controlled substance therapy remain within regulatory parameters.
Friday, September 30, 2022, 11:05 a.m. PST
Learning objectives
• Integrate urine drug testing to support the treatment and monitoring of pain management patients.
• Describe the limitations of various screening and quantitative urine drug tests.
• Interpret urine drug testing results from pain management patients.
Learn more about
Controlled substance monitoring
Targeted testing for opioid use
Digital resources
AACC Laboratory Medicine Practice Guidelines
New High-Resolution Targeted Opioid Screen
Laboratory Detection of Opioids
Printable documents
Pain Management Testing Services Overview
Controlled Substance Monitoring Brochure
Targeted Opioid Monitoring Flyer
Opioids Pharmacokinetics Chart
